Protective role of irisin on bone in osteoporosis: a systematic review of rodent studies
- PMID: 40192854
- DOI: 10.1007/s00198-025-07470-9
Protective role of irisin on bone in osteoporosis: a systematic review of rodent studies
Abstract
Osteoporosis is defined as a bone disease that is characterized by a reduction in bone mass and an elevated risk of fracture. Irisin, which is regulated by peroxisome proliferator-activated receptor γ coactivator-1α (PGC1α), is a muscle-derived protein that is induced by exercise. A number of studies have indicated that irisin has the capacity to stimulate bone formation and decrease bone resorption, which plays a crucial role in bone metabolism. Regular exercise has been demonstrated to be an effective method for maintaining and enhancing bone health, with irisin emerging as a key regulatory molecule in this process. In light of these findings, irisin represents a promising approach for the treatment of osteoporosis. Animal studies are an essential part of the clinical trial process, as they are used to assess the efficacy and potential risks associated with proposed interventions. The objective of this review was to conduct a systematic review of animal studies and discuss the effects and mechanisms of irisin on bone in osteoporosis. A systematic search was conducted across eight databases, resulting in the identification, data extraction, and quality assessment of 27 articles. The results demonstrate that irisin can restore the steady state of bone homeostasis through the activation or inhibition of multiple pathways. It can ameliorate the microstructural damage and bone turnover caused by osteoporosis; improve the response to bone mechanical stress; promote the proliferation, differentiation, and mineralization of osteoblasts; and play an important role in exercise-based prevention and treatment of osteoporosis. Furthermore, irisin can attenuate inflammatory changes in bone and participate in the regulation of cell death. This review was registered at PROSPERO (CRD42024539678).
Keywords: Bone loss; Exercise; Irisin; Osteoporosis; Rodent.
© 2025. International Osteoporosis Foundation and Bone Health and Osteoporosis Foundation.
Conflict of interest statement
Declarations. Ethical approval: As this study is a systematic review, it does not involve direct participation of human or animal subjects and thus did not require ethical approval. However, all studies included in this review were conducted in accordance with ethical standards as stated in their respective publications. Conflicts of interest: None. PROSPERO: CRD42024539678
Similar articles
-
Irisin as an agent for protecting against osteoporosis: A review of the current mechanisms and pathways.J Adv Res. 2024 Aug;62:175-186. doi: 10.1016/j.jare.2023.09.001. Epub 2023 Sep 3. J Adv Res. 2024. PMID: 37669714 Free PMC article. Review.
-
Role of the Myokine Irisin on Bone Homeostasis: Review of the Current Evidence.Int J Mol Sci. 2021 Aug 24;22(17):9136. doi: 10.3390/ijms22179136. Int J Mol Sci. 2021. PMID: 34502045 Free PMC article. Review.
-
Role of irisin in effects of chronic exercise on muscle and bone in ovariectomized mice.J Bone Miner Metab. 2021 Jul;39(4):547-557. doi: 10.1007/s00774-020-01201-2. Epub 2021 Feb 10. J Bone Miner Metab. 2021. PMID: 33566209
-
Exerkine FNDC5/irisin-enriched exosomes promote proliferation and inhibit ferroptosis of osteoblasts through interaction with Caveolin-1.Aging Cell. 2024 Aug;23(8):e14181. doi: 10.1111/acel.14181. Epub 2024 Apr 30. Aging Cell. 2024. PMID: 38689463 Free PMC article.
-
Role of irisin in physiology and pathology.Front Endocrinol (Lausanne). 2022 Sep 26;13:962968. doi: 10.3389/fendo.2022.962968. eCollection 2022. Front Endocrinol (Lausanne). 2022. PMID: 36225200 Free PMC article. Review.
References
-
- Compston JE, McClung MR, Leslie WD (2019) Osteoporosis. Lancet 393:364–376. https://doi.org/10.1016/S0140-6736(18)32112-3 - DOI - PubMed
-
- Glaser DL, Kaplan FS (1997) Osteoporosis. Definition and clinical presentation. Spine 22:12S-16S. https://doi.org/10.1097/00007632-199712151-00003 - DOI - PubMed
-
- Brown C (2017) Osteoporosis: staying strong. Nature 550:S15–S17. https://doi.org/10.1038/550S15a - DOI - PubMed
-
- Cummings SR, Melton LJ (2002) Epidemiology and outcomes of osteoporotic fractures. Lancet 359:1761–1767. https://doi.org/10.1016/S0140-6736(02)08657-9 - DOI - PubMed
-
- Rachner TD, Khosla S, Hofbauer LC (2011) Osteoporosis: now and the future. Lancet (London, England) 377:1276–1287. https://doi.org/10.1016/S0140-6736(10)62349-5 - DOI - PubMed
Publication types
Grants and funding
LinkOut - more resources
Full Text Sources